Vicore Pharma Holding AB Stock price

Equities

VICO

SE0007577895

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 07:59:46 2024-03-28 am EDT 5-day change 1st Jan Change
14.68 SEK -2.13% Intraday chart for Vicore Pharma Holding AB -5.53% +3.53%
Sales 2023 - Sales 2024 * 104M 9.73M Capitalization 1.68B 157M
Net income 2023 -311M -29.08M Net income 2024 * -151M -14.12M EV / Sales 2023 -
Net cash position 2023 * 388M 36.33M Net cash position 2024 * 274M 25.59M EV / Sales 2024 * 13.5 x
P/E ratio 2023
-4.4 x
P/E ratio 2024 *
-11.1 x
Employees 24
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.02%
More Fundamentals * Assessed data
Dynamic Chart
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates CI
Vicore Pharma Holding AB Appoints Bertil Lindmark as Chief Medical Officer CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vicore Pharma Holding AB Announces the Nomination Committee for the 2024 Annual General Meeting CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106 CI
Certain Shares of Vicore Pharma Holding AB are subject to a Lock-Up Agreement Ending on 11-SEP-2023. CI
Vicore Pharma's New CEO to Formally Take Office MT
Vicore Pharma Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Vicore Pharma Holding AB Reports Data from EndoPAT® Exploratory Trial CI
Vicore Pharma Names New CEO to Start in September MT
More news

Latest transcript on Vicore Pharma Holding AB

1 day-1.60%
1 week-5.02%
Current month+4.68%
1 month+2.22%
3 months+2.07%
6 months-3.02%
Current year+4.09%
More quotes
1 week
14.50
Extreme 14.5
15.68
1 month
13.90
Extreme 13.9
17.10
Current year
12.84
Extreme 12.84
17.10
1 year
12.36
Extreme 12.36
26.90
3 years
12.20
Extreme 12.2
37.45
5 years
6.82
Extreme 6.82
38.30
10 years
5.70
Extreme 5.7
40.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 23-09-08
Director of Finance/CFO - 16-12-31
Chief Tech/Sci/R&D Officer - 20-11-15
Members of the board TitleAgeSince
Chairman 57 17-12-31
Director/Board Member 66 17-12-31
Director/Board Member 64 22-12-31
More insiders
Date Price Change Volume
24-03-28 14.68 -2.13% 132 500
24-03-27 15 +2.32% 136,665
24-03-26 14.66 -2.14% 134,876
24-03-25 14.98 -2.73% 109,498
24-03-22 15.4 -0.90% 115,795

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 05:30 am EDT

More quotes
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15 SEK
Average target price
68.6 SEK
Spread / Average Target
+357.33%
Consensus
  1. Stock
  2. Equities
  3. Stock Vicore Pharma Holding AB - Nasdaq Stockholm